Sign Out
Renal impairment: There is limited experience with Repatha in patients with severe renal impairment (defined as eGFR < 30 mL/min/1.73 m2) (see Pharmacology: Pharmacokinetics under Actions). Repatha should be used with caution in patients with severe renal impairment.
Hepatic impairment: In patients with moderate hepatic impairment, a reduction in total evolocumab exposure was observed that may lead to a reduced effect on LDL-C reduction. Therefore, close monitoring may be warranted in these patients.
Patients with severe hepatic impairment (Child-Pugh class C) have not been studied (see Pharmacology: Pharmacokinetics under Actions). Repatha should be used with caution in patients with severe hepatic impairment.
Dry natural rubber: The needle cover of the glass pre-filled syringe/autoinjector is made from dry natural rubber (a derivative of latex), which may cause allergic reactions.
Sodium content: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially 'sodium-free'.
Effects on ability to drive and use machines: Repatha has no known influence on the ability to drive and use machines.
Continue with Google